Serum screening for Down syndrome and open neural tube defects - Testing against the criteria of the Dutch Health Council for genetic screening;Serumscreening bij zwangeren voor Down-syndroom en open neurale-buisdefecten; toetsing aan de Gezondheidsraad-criteria voor genetische screening

Nederlands Tijdschrift voor Geneeskunde

Volumn 140, Issue 2, 1996, Pages 85-89

  Wildhagen, M F ^a   Christiaens, G C M L ^b   Habbema, J D F ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b Diviste Obstetrie en Gynaecologie ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DOWN SYNDROME; GENETIC SCREENING; HUMAN; NETHERLANDS; NEURAL TUBE DEFECT; POPULATION RESEARCH;

ALPHA-FETOPROTEINS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; ESTRIOL; FEMALE; GENETIC COUNSELING; HUMANS; NETHERLANDS; NEURAL TUBE DEFECTS; PREGNANCY; PRENATAL DIAGNOSIS; PUBLIC HEALTH ADMINISTRATION;

EID: 0030033004     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Boer-van den Berg JMA van den, Dupuis HM. De triple-serumtest voor detectie van Down-syndroom en neurale-buisdefecten: het probleem van een risicoschattende test. Ned Tijdschr Geneeskd 1993; 137:1286-9.
2. Beekhuis JR, Mantingh A, Wolf BTHM de, Lith JMM van. Breed ASPM. Serumscreening van zwangeren op foetale neurale-buisde-fecten èn Down-syndroom: eerste ervaringen in Nederland. Ned Tijdschr Geneeskd 1993;137:1303-7.
3. Giltay JC. De triple-serumtest voor detectie van Down-syndroom en neurale-buisdefecten: het probleem van een risicoschattende test [ingezonden]. Ned Tijdschr Geneeskd 1993;137:1681.
4. Beekhuís JR, Mantingh A, Wolf BTHM de. Lith JMM van, Breed ASPM. De triple-serumtest voor detectie van Down-syndroom en neurale-buisdefecten: het probleem van een risicoschattende test [ingezonden]. Ned Tijdschr Geneeskd 1993;137:1682.
5. Christiaens GCML. Maternale serumscreening - een alternatief voor invasieve diagnostiek? Tijdschrift voor Verloskundigen 1994; 19:120-4.
6. Gezondheidsraad. Commissie Screening Erfelijke en Aangeboren Aandoeningen. Genetische screening. Nr 22. Den Haag: Gezondheidsraad, 1994.
7. Thornton JG, Hewison J, Lilford RJ, Vail A. A randomised trial of three methods of giving information about prenatal testing. BMJ 1995 [ter perse].
8. The Royal College of Obstetricians and Gynaecologists (RCOG). Report of the RCOG Working Party on biochemical markers and the detection of Down's syndrome. London: RCOG, 1993.
9. Boyd PA. Serum screening for Down's syndrome. Private patients may receive less counselling [letter]. BMJ 1994;309:1372.
10. Reynolds T, John R. Serum screening for Down's syndrome. National policy would ensure consistency [letter]. BMJ 1994;309:1372-3.
11. Allaby M. Serum screening for Down's syndrome. Counselling should emphasise possible outcomes of screening [letter]. BMJ 1994; 309:1373.
12. Barrow M, Falconer Smith J, Stewart C. Serum screening for Down's syndrome. Keeping the concept of risk simple [letter]. BMJ 1994;309:1373.
13. Kriek R, Korenromp MJ, Hagenaars AM, Christiaens GCML, Bruinse HW. Screening op foetale neuraalbuisdefecten. Alfa-foetoproleïneconcemratie in maternaal serum. Med Contact 1994;49: 321-4.
14. Gill M, Murday V, Slack J. An economic appraisal of screening for Down's syndrome in pregnancy using maternal age and serum alpha fetoprotein concentration. Soc Sci Med 1987;24:725-31.
15. Spencer K, Carpenter P. Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin. BMJ 1993;307:764-9.
16. Piggott M, Wilkinson P, Bennett J. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). Journal of Medical Screening 1994;1: 45-9.
17. Gezondheidsraad. Commissie Lichaamsmateriaal voor bijzondere doeleinden. Naar goed gebruik. Lichaamsmateriaal in de gezondheidszorg. Nr i. Den Haag: Gezondheidsraad, 1994.
18. Hook EB. Prevalence, risks and recurrence. In: Brock DJH, Rodeck CH, Ferguson-Smith MA, editors. Prenatal diagnosis and screening. London: Churchill Livingstone, 1992;351-92.
19. Cornel MC, Walle HEK de, Haveman TM, Spreen JA, Breed AC, Kate LP ten. Prevalenties bij de geboorte van meer dan 30 aangeboren afwijkingen in Noord-Nederland. Ned Tijdschr Geneeskd 1991; 135:2032-6.
20. Baird PA, Sadovnick AD. Life expectancy in Down syndrome. J Pediatr 1987;110:849-54.
21. Gezondheidsraad. Neuraalbuisdefecten. Nr 15. Den Haag: Gezondheidsraad. 1988.
22. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-93.
23. Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992;80:353-8.
24. Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 1992;305:391-4.
25. Burton BK, Prins GS, Verp MS. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Am J Obstet Gynecol 1993;169:526-30.
26. Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol 1993;81: 72-7.
27. Goodburn SF, Yates JRW, Raggatt PR, Carr C, Ferguson-Smith ME, Kershaw AJ, et al. Second-trimester maternal serum screening using alpha-fetoproiein, human chorionic gonadotrophin, and unconjugated oestnol: experience of a regional programme. Prenat Diagn 1994;14:391-402.
28. Wald NJ, Cuckle HS. Biochemical screening, In: Brock DJH, Rodeck CH, Ferguson-Smith MA, editors. Prenatal diagnosis and screening. London; Churchill Livingstone. 1992:563-77.
29. Crandall BF, Robinson L, Grau P. Risks associated with an elevated maternal serum alpha-fetoprotein level. Am J Obstet Gynecol 1991; 165:581-6.
30. Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M. The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 1992; 80:83-6.
31. Spijker HG van, Korenromp M. Iedema-Kuiper HR, Bergsma J, Beemer FA, Christiaens GCML Opvang na zwangerschapsbeêin-diging op genetische indicatie: ervaringen van de betrokken vrouwen en hun partners. Ned Tijdschr Geneeskd 1992;136:477-81.
32. Heckerling PS, Verp MS. A cost-effectiveness analysis of amniocentesis and chorionic villus sampling for prenatal genetic testing. Med Care 1994;32:863-80.
33. Marteau TM, Slack J. Psychological implications of prenatal diagnosis for patients and health professionals. In: Brock DJH, Rodeck CH, Ferguson-Smith MA, editors. Prenatal diagnosis and screening. London: Churchill Livingstone, 1992:663-73.
34. Henderson JB. An economic appraisal of the benefits of screening for open spina bifida. Soc Sci Med 1982;16:545-60.
35. Layde PM, Allmen SD von, Oakley GP jr. Maternal serum alpha-fetoprotein screening: a cost-benefit analysis. Am J Public Health 1979;69:566-73.
36. Nightingale EO, Meister SB. Prenatal screening, policies, and values: the example of neural tube defects. Cambridge, Mass.: Harvard University, 1987.
37. Tosi LL, Detsky AS, Roye DP, Morden ML. When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings? Can Med Assoc J 1987:136:255-65.
38. Sheldon TA, Simpson J. Appraisal of a new scheme for prenatal screening for Down's syndrome. BMJ 1991;302:1133-6.
39. Shackley P, McGuire A, Boyd PA, Dennis J, Fitchett M, Kay J, et al. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome. J Public Health Med 1993;15:175-84.
40. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994;330:1114-8.
41. Seror V, Muller F, Moatti JP, Le Gales C, Boue A. Economic assessment of maternal serum screening for Down's syndrome using human chorionic gonadotropin. Prenat Diagn 1993;13:281-92.